<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="xla" content-type="chapter" from-where="body" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">gene</book-id>
    <book-title-group>
      <book-title>GeneReviews<sup>&#x000ae;</sup></book-title>
    </book-title-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Adam</surname>
          <given-names>Margaret P</given-names>
        </name>
        <role>Editor-in-Chief</role>
      </contrib>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ardinger</surname>
          <given-names>Holly H</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Pagon</surname>
          <given-names>Roberta A</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Wallace</surname>
          <given-names>Stephanie E</given-names>
        </name>
      </contrib>
      <role>Senior Editors</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Bean</surname>
          <given-names>Lora JH</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Mefford</surname>
          <given-names>Heather C</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Stephens</surname>
          <given-names>Karen</given-names>
        </name>
      </contrib>
      <role>Molecular Genetics</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Amemiya</surname>
          <given-names>Anne</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ledbetter</surname>
          <given-names>Nikki</given-names>
        </name>
      </contrib>
      <role>Genetic Counseling</role>
    </contrib-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>1993</year>
    </pub-date>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>2017</year>
    </pub-date>
    <issn>2372-0697</issn>
    <publisher>
      <publisher-name>University of Washington, Seattle</publisher-name>
      <publisher-loc>Seattle (WA)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 1993-2017, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved.</copyright-statement>
      <copyright-year>2017</copyright-year>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK138602/">
        <license-p>GeneReviews&#x000ae; chapters are owned by the University of Washington. Permission is hereby granted to reproduce, distribute, and translate copies of content materials for noncommercial research purposes only, provided that (i) credit for source (<ext-link ext-link-type="uri" xlink:href="http://www.genereviews.org/">http://www.genereviews.org/</ext-link>) and copyright (&#x000a9; 1993-2017 University of Washington) are included with each copy; (ii) a link to the original material is provided whenever the material is published elsewhere on the Web; and (iii) reproducers, distributors, and/or translators comply with the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>. No further modifications are allowed. For clarity, excerpts of GeneReviews chapters for use in lab reports and clinic notes are a permitted use.</license-p>
        <license-p>For more information, see the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>.</license-p>
        <license-p>For questions regarding permissions or whether a specified use is allowed, contact: <email>admasst@uw.edu</email>.</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Genetics</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Medicine</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Diseases</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="ednotes">
      <p content-type="genetic_counseling">
<italic toggle="yes">Genetic counseling is the process of
providing individuals and families with information on the nature, inheritance,
and implications of genetic disorders to help them make informed medical and
personal decisions. The following section deals with genetic risk assessment and
the use of family history and genetic testing to clarify genetic status for
family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with
a genetics professional</italic>. &#x02014;ED.</p>
      <p content-type="resources">
<italic toggle="yes">GeneReviews staff has selected the following disease-specific and/or
umbrella support organizations and/or registries for the benefit of individuals
with this disorder and their families. GeneReviews is not responsible for the
information provided by other organizations. For information on selection
criteria, click <related-object source-id="gene" document-id="app4">here</related-object>.</italic></p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <book-part-id book-part-id-type="pmcid">xla</book-part-id>
      <title-group>
        <title>X-Linked Agammaglobulinemia</title>
        <alt-title alt-title-type="alt-title">Synonyms: Bruton's Agammaglobulinemia, XLA</alt-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Smith</surname>
            <given-names>CI Edvard</given-names>
          </name>
          <degrees>MD, PhD</degrees>
          <aff>Karolinska Institutet<break/>Stockholm, Sweden</aff>
          <email>edvard.smith@ki.se</email>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Bergl&#x000f6;f</surname>
            <given-names>Anna</given-names>
          </name>
          <degrees>VMD, PhD</degrees>
          <aff>Karolinska Institutet<break/>Stockholm, Sweden</aff>
          <email>anna.berglof@ki.se</email>
        </contrib>
      </contrib-group>
      <pub-history>
        <date date-type="created">
          <day>5</day>
          <month>4</month>
          <year>2001</year>
        </date>
        <date date-type="updated">
          <day>4</day>
          <month>8</month>
          <year>2016</year>
        </date>
        <date date-type="revised">
          <day>4</day>
          <month>11</month>
          <year>2004</year>
        </date>
      </pub-history>
      <related-object link-type="parent-book-link" source-id="gene">GeneReviews<sup>&#x000ae;</sup></related-object>
      <related-object link-type="previous-part-link" source-id="gene" document-id="x-ald" document-type="chapter">X-Linked Adrenoleukodystrophy</related-object>
      <related-object link-type="next-part-link" source-id="gene" document-id="mtm" document-type="chapter">X-Linked Centronuclear Myopathy</related-object>
      <abstract id="xla.Summary">
        <title>Summary</title>
        <sec>
          <title>Clinical characteristics</title>
          <p>X-linked agammaglobulinemia (XLA) is characterized by recurrent bacterial infections in affected males in the first two years of life. Recurrent otitis is the most common infection prior to diagnosis. Conjunctivitis, sinopulmonary infections, diarrhea, and skin infections are also frequently seen. Approximately 60% of individuals with XLA are recognized as having immunodeficiency when they develop a severe, life-threatening infection such as pneumonia, empyema, meningitis, sepsis, cellulitis, or septic arthritis. <italic toggle="yes">S pneumoniae</italic> and <italic toggle="yes">H influenzae</italic> are the most common organisms found prior to diagnosis and may continue to cause sinusitis and otitis after diagnosis and the initiation of gammaglobulin substitution therapy. Severe, difficult-to-treat enteroviral infections (often manifest as dermatomyositis or chronic meningoencephalitis) can be prevented by this treatment. The prognosis for individuals with XLA has improved markedly in the last 25 years as a result of earlier diagnosis, the development of preparations of gammaglobulin that allow normal concentrations of serum IgG to be achieved, and more liberal use of antibiotics.</p>
        </sec>
        <sec>
          <title>Diagnosis/testing</title>
          <p>The diagnosis of XLA is suspected in males with early-onset bacterial infections, marked reduction in all classes of serum immunoglobulins, and absent B cells (CD19+ cells); the decrease in the number of B cells is the most consistent and distinctive feature. Adenoids and tonsils are frequently rudimentary and lymph nodes are reduced in size. Having a maternal uncle or male cousin with absent B cells makes the diagnosis almost certain. The diagnosis is established (or confirmed) in males who have a hemizygous <italic toggle="yes">BTK</italic> pathogenic variant and females who have a heterozygous <italic toggle="yes">BTK</italic> pathogenic variant.</p>
        </sec>
        <sec>
          <title>Management</title>
          <p><italic toggle="yes">Treatment of manifestations:</italic> The mainstay of treatment is gammaglobulin substitution therapy (by weekly subcutaneous injection or intravenous infusion every 2-4 weeks) to prevent bacterial infections; some centers use chronic prophylactic antibiotics to prevent infections.</p>
          <p><italic toggle="yes">Prevention of secondary complications:</italic> The most common secondary complications of XLA are chronic sinusitis, chronic lung disease, inflammatory bowel disease, and enteroviral infection. Generous use of antibiotics can decrease the incidence of chronic sinusitis and lung disease. Diagnosis and treatment of bowel infections may decrease the risk of inflammatory bowel disease.</p>
          <p><italic toggle="yes">Agents/circumstances to avoid:</italic> Live viral vaccines, particularly oral polio vaccine; inactivated polio vaccine rather than live oral polio vaccine should be given to patients and their family contacts.</p>
          <p><italic toggle="yes">Evaluation of relatives at risk:</italic> Molecular genetic testing of at-risk male relatives as soon after birth as possible ensures that gammaglobulin substitution therapy is initiated as soon as possible in affected individuals.</p>
        </sec>
        <sec>
          <title>Genetic counseling</title>
          <p>XLA is inherited in an X-linked manner. The risk to the sibs depends on the carrier status of the mother: if the mother is heterozygous for a <italic toggle="yes">BTK</italic> pathogenic variant, there is a 50% chance of transmitting the <italic toggle="yes">BTK</italic> pathogenic variant in each pregnancy; males who inherit the pathogenic variant will be affected; females who inherit the pathogenic variant will be carriers. All daughters of a male proband will inherit the <italic toggle="yes">BTK</italic> pathogenic variant and will be carriers; sons are not affected. Once the <italic toggle="yes">BTK</italic> pathogenic variant has been identified in an affected family member, carrier testing for at-risk females is possible and prenatal testing for a pregnancy at increased risk and preimplantation genetic diagnosis are possible options.</p>
        </sec>
      </abstract>
    </book-part-meta>
    <body>
      <sec id="xla.Diagnosis">
        <title>Diagnosis</title>
        <sec id="xla.Suggestive_Findings">
          <title>Suggestive Findings</title>
          <p>X-linked agammaglobulinemia (XLA) <bold>should be suspected</bold> in an individual with the following clinical history, laboratory findings, and family history.</p>
          <p><bold>Clinical history.</bold> Any of the following:</p>
          <list list-type="bullet">
            <list-item>
              <p>Recurrent otitis, pneumonitis, sinusitis, and conjunctivitis starting before age five years</p>
            </list-item>
            <list-item>
              <p>A severe life-threatening bacterial infection such as sepsis, meningitis, cellulitis, or empyema</p>
            </list-item>
            <list-item>
              <p>Paucity of lymphoid tissue (small adenoids, tonsils, and lymph nodes on physical examination)</p>
            </list-item>
          </list>
          <p>
            <bold>Laboratory findings</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p><bold>Marked reduction in all classes of serum immunoglobulins</bold> [<xref ref-type="bibr" rid="xla.REF.lederman.1985.145">Lederman &#x00026; Winkelstein 1985</xref>, <xref ref-type="bibr" rid="xla.REF.conley.2005.216">Conley et al 2005</xref>]</p>
              <list list-type="bullet">
                <list-item>
                  <p>The serum IgG concentration is typically &#x0003c;200 mg/dL (2 g/L). Most but not all individuals with XLA do have some measurable serum IgG, usually between 100 and 200 mg/dL, and ~10% of individuals have serum concentration of IgG &#x0003e;200 mg/dL.</p>
                </list-item>
                <list-item>
                  <p>The serum concentrations of IgM and IgA are typically &#x0003c;20 mg/dL. Particular attention should be given to serum IgM concentration. Although decreased serum concentration of IgG and IgA can be seen in children with a constitutional delay in immunoglobulin production, low serum IgM concentration is almost always associated with immunodeficiency.</p>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <p><bold>Markedly reduced numbers of B lymphocytes</bold> (CD 19+ cells) in the peripheral circulation (&#x0003c;1%) [<xref ref-type="bibr" rid="xla.REF.conley.1985.3070">Conley 1985</xref>, <xref ref-type="bibr" rid="xla.REF.nonoyama.1998.3925">Nonoyama et al 1998</xref>]</p>
            </list-item>
            <list-item>
              <p><bold>Antibody titers to vaccine antigens.</bold> Individuals with XLA fail to make antibodies to vaccine antigens like tetanus, <italic toggle="yes">H influenzae</italic>, or <italic toggle="yes">S pneumoniae.</italic></p>
            </list-item>
            <list-item>
              <p><bold>Severe neutropenia</bold> in ~10%-25% of individuals at the time of diagnosis, usually in association with pseudomonas or staphylococcal sepsis [<xref ref-type="bibr" rid="xla.REF.conley.2002.566">Conley &#x00026; Howard 2002</xref>]</p>
            </list-item>
          </list>
          <p><bold>Family history</bold> of immunodeficiency consistent with X-linked inheritance</p>
        </sec>
        <sec id="xla.Establishing_the_Diagnosis">
          <title>Establishing the Diagnosis</title>
          <p><bold>Male proband.</bold> The diagnosis of XLA <bold>is established</bold> in a male proband with suggestive clinical and laboratory findings and identification of a hemizygous pathogenic variant in <italic toggle="yes">BTK</italic> by molecular genetic testing (see <xref ref-type="table" rid="xla.T.summary_of_molecular_genetic_testi">Table 1</xref>).</p>
          <p>Molecular genetic testing approaches can include <bold>single-gene testing</bold>, use of a <bold>multi-gene panel</bold>, and <bold>more comprehensive</bold>
<bold>genomic testing</bold>:</p>
          <list list-type="bullet">
            <list-item>
              <p><bold>Single-gene testing.</bold> Sequence analysis of <italic toggle="yes">BTK</italic> is performed first followed by gene-targeted deletion/duplication analysis if no pathogenic variant is found.Note: (1) Because approximately 3%-5% of individuals with a <italic toggle="yes">BTK</italic> pathogenic variant have large deletions that include all or part of <italic toggle="yes">BTK</italic> and the closely linked gene <italic toggle="yes">TIMM8A</italic> (also called <italic toggle="yes">DDP</italic>) resulting in XLA and <related-object link-type="booklink" source-id="gene" document-id="ddon" document-type="chapter">deafness-dystonia-optic neuropathy syndrome</related-object> (DDS; also called Mohr-Tranebj&#x000e6;rg syndrome) [<xref ref-type="bibr" rid="xla.REF.richter.2001.107">Richter et al 2001</xref>, <xref ref-type="bibr" rid="xla.REF.sediv_.2007.640">Sediv&#x000e1; et al 2007</xref>], additional testing with chromosomal microarray analysis (CMA) may be warranted. (2) For individuals with clinical features of XLA and DDS, consider CMA testing first.</p>
            </list-item>
            <list-item>
              <p><bold>A multi-gene panel</bold> that includes <italic toggle="yes">BTK</italic> and other genes of interest (see <xref ref-type="sec" rid="xla.Differential_Diagnosis">Differential Diagnosis</xref>) may also be considered. Note: (1) The genes included in the panel and the diagnostic sensitivity of the testing used for each gene vary by laboratory and over time. (2) Methods used in a panel may include sequence analysis, deletion/duplication analysis, and/or other non-sequencing based tests.</p>
            </list-item>
            <list-item>
              <p><bold>More comprehensive genomic testing</bold> (when available) including exome sequencing and genome sequencing may be considered if serial single-gene testing (and/or use of a multi-gene panel that includes <italic toggle="yes">BTK</italic>) fails to confirm a diagnosis in an individual with features of XLA. Such testing may also provide or suggest a diagnosis not previously considered (e.g., mutation of a different gene or genes that results in a similar clinical presentation). For more information on comprehensive genome sequencing click <related-object link-type="booklink" source-id="gene" document-id="app5" document-type="appendix" object-id="app5.Comprehensive_Genome_Sequencing" object-type="sec">here</related-object>.</p>
            </list-item>
          </list>
          <table-wrap id="xla.T.summary_of_molecular_genetic_testi" orientation="portrait" position="anchor">
            <label>Table 1. </label>
            <caption>
              <p>Summary of Molecular Genetic Testing Used in X-Linked Agammaglobulinemia (XLA)</p>
            </caption>
            <table frame="hsides" rules="groups">
              <thead>
                <tr>
                  <th id="hd_h_xla.T.summary_of_molecular_genetic_testi_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Gene&#x000a0;<sup>1</sup></th>
                  <th id="hd_h_xla.T.summary_of_molecular_genetic_testi_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Test Method</th>
                  <th id="hd_h_xla.T.summary_of_molecular_genetic_testi_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Proportion of Probands with a Pathogenic Variant&#x000a0;<sup>2</sup> Detectable by This Method</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td headers="hd_h_xla.T.summary_of_molecular_genetic_testi_1_1_1_1" rowspan="3" valign="middle" align="left" scope="row" colspan="1">
                    <italic toggle="yes">BTK</italic>
                  </td>
                  <td headers="hd_h_xla.T.summary_of_molecular_genetic_testi_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Sequence analysis&#x000a0;<sup>3,&#x000a0;4,&#x000a0;5</sup></td>
                  <td headers="hd_h_xla.T.summary_of_molecular_genetic_testi_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">92%</td>
                </tr>
                <tr>
                  <td headers="hd_h_xla.T.summary_of_molecular_genetic_testi_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Gene-targeted deletion/duplication analysis&#x000a0;<sup>6</sup></td>
                  <td headers="hd_h_xla.T.summary_of_molecular_genetic_testi_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">8%</td>
                </tr>
                <tr>
                  <td headers="hd_h_xla.T.summary_of_molecular_genetic_testi_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">CMA&#x000a0;<sup>7</sup></td>
                  <td headers="hd_h_xla.T.summary_of_molecular_genetic_testi_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">3%-5%&#x000a0;<sup>8</sup></td>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <fn id="xla.TF.1.1">
                <label>1. </label>
                <p>See <related-object source-id="gene" document-id="xla" object-id="xla.molgen.TA">Table A. Genes and Databases</related-object> for chromosome locus and protein.</p>
              </fn>
              <fn id="xla.TF.1.2">
                <label>2. </label>
                <p>See <xref ref-type="sec" rid="xla.Molecular_Genetics">Molecular Genetics</xref> for information on allelic variants detected in this gene.</p>
              </fn>
              <fn id="xla.TF.1.3">
                <label>3. </label>
                <p>Sequence analysis detects variants that are benign, likely benign, of uncertain significance, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and missense, nonsense, and splice site variants; typically, exon or whole-gene deletions/duplications are not detected. For issues to consider in interpretation of sequence analysis results, click <related-object link-type="booklink" source-id="gene" document-id="app2" document-type="appendix">here</related-object>.</p>
              </fn>
              <fn id="xla.TF.1.4">
                <label>4. </label>
                <p>Lack of amplification by PCR prior to sequence analysis can suggest a putative (multi)exon or whole-gene deletion on the X chromosome in affected males; confirmation requires additional testing by gene-targeted deletion/duplication analysis.</p>
              </fn>
              <fn id="xla.TF.1.5">
                <label>5. </label>
                <p>Several deep intronic pathogenic variants that would not be detected by routine sequence analysis have been reported [<xref ref-type="bibr" rid="xla.REF.kralovicova.2011.7077">Kralovicova et al 2011</xref>, <xref ref-type="bibr" rid="xla.REF.mohiuddin.2013.1717">Mohiuddin et al 2013</xref>, <xref ref-type="bibr" rid="xla.REF.rattanachartnarong.2014.431">Rattanachartnarong et al 2014</xref>]. Pathogenic intronic variants that cause splicing defects may be detected by targeted sequencing or analysis of mRNA.</p>
              </fn>
              <fn id="xla.TF.1.6">
                <label>6. </label>
                <p>Gene-targeted deletion/duplication analysis detects intragenic deletions or duplications. Methods that may be used include: quantitative PCR, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a gene-targeted microarray designed to detect single-exon deletions or duplications. These methods will detect single-exon up to whole-gene deletions; however, breakpoints of large deletions and/or deletion of adjacent genes may not be detected by these methods.</p>
              </fn>
              <fn id="xla.TF.1.7">
                <label>7. </label>
                <p>Chromosomal microarray analysis (CMA) using oligonucleotide arrays or SNP arrays. CMA designs in current clinical use target the Xq22.1 region.</p>
              </fn>
              <fn id="xla.TF.1.8">
                <label>8. </label>
                <p>Approximately 3%-5% of individuals (a subset of the 8% detected by gene-targeted deletion/duplication analysis) with a <italic toggle="yes">BTK</italic> pathogenic variant have a large deletion that extends through the closely linked gene <italic toggle="yes">TIMM8A</italic> (also called <italic toggle="yes">DDP</italic>) and sometimes through <italic toggle="yes">TAF7L</italic> and <italic toggle="yes">DRP2</italic> [<xref ref-type="bibr" rid="xla.REF.richter.2001.107">Richter et al 2001</xref>, <xref ref-type="bibr" rid="xla.REF.sediv_.2007.640">Sediv&#x000e1; et al 2007</xref>]. Individuals with these multi-gene deletions have XLA and <related-object link-type="booklink" source-id="gene" document-id="ddon" document-type="chapter">deafness-dystonia-optic neuropathy syndrome</related-object> (DDS; also called Mohr-Tranebj&#x000e6;rg syndrome).</p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
        </sec>
      </sec>
      <sec id="xla.Clinical_Characteristics">
        <title>Clinical Characteristics</title>
        <sec id="xla.Clinical_Description">
          <title>Clinical Description</title>
          <p>Males with X-linked agammaglobulinemia (XLA) are usually well for the first few months of life because they are protected by transplacentally acquired maternal immunoglobulin. Typically, affected males develop recurrent bacterial infections in the first two years of life and are recognized as having immunodeficiency before age five years [<xref ref-type="bibr" rid="xla.REF.ochs.1996.287">Ochs &#x00026; Smith 1996</xref>, <xref ref-type="bibr" rid="xla.REF.conley.2002.566">Conley &#x00026; Howard 2002</xref>, <xref ref-type="bibr" rid="xla.REF.plebani.2002.221">Plebani et al 2002</xref>, <xref ref-type="bibr" rid="xla.REF.winkelstein.2006.193">Winkelstein et al 2006</xref>].</p>
          <p>Recurrent otitis is the most common infection prior to diagnosis. Conjunctivitis, sinopulmonary infections, diarrhea, and skin infections are also frequently seen. Approximately 60% of individuals with XLA are recognized as having immunodeficiency when they develop a severe, life-threatening infection such as pneumonia, empyema, meningitis, sepsis, cellulitis, or septic arthritis. Because males with XLA fail to make antibodies to vaccine antigens like tetanus, <italic toggle="yes">H influenzae</italic>, or <italic toggle="yes">S pneumoniae,</italic> the latter two organisms are the most commonly seen prior to diagnosis of XLA and they may continue to cause sinusitis and otitis even after diagnosis and the initiation of gammaglobulin substitution therapy [<xref ref-type="bibr" rid="xla.REF.lederman.1985.145">Lederman &#x00026; Winkelstein 1985</xref>, <xref ref-type="bibr" rid="xla.REF.conley.2005.216">Conley et al 2005</xref>].</p>
          <p>Individuals with XLA are not vulnerable to the majority of viral infections; however, they are susceptible to severe and chronic enteroviral infections (often manifesting as dermatomyositis or chronic meningoencephalitis) [<xref ref-type="bibr" rid="xla.REF.wilfert.1977.1485">Wilfert et al 1977</xref>, <xref ref-type="bibr" rid="xla.REF.bearden.2016">Bearden et al 2016</xref>]. In the past, 5%-10% of individuals with XLA developed vaccine-associated polio after vaccination with the live attenuated oral polio vaccine. Since the mid-1980s, when gammaglobulin substitution therapy became available, the incidence of chronic enteroviral infection has markedly decreased in individuals with XLA. However, some individuals still develop enteroviral encephalitis and some have neurologic deterioration of unknown etiology [<xref ref-type="bibr" rid="xla.REF.misbah.1992.266">Misbah et al 1992</xref>, <xref ref-type="bibr" rid="xla.REF.ziegner.2002.19">Ziegner et al 2002</xref>].</p>
          <p>Like all individuals with antibody deficiencies, persons with XLA are highly susceptible to giardia infection. They may also develop persistent mycoplasma infections. Infections with unusual organisms, like <italic toggle="yes">Flexispira</italic> or <italic toggle="yes">Helicobacter cinaedi</italic>, may also be troublesome [<xref ref-type="bibr" rid="xla.REF.cuccherini.2000.121">Cuccherini et al 2000</xref>, <xref ref-type="bibr" rid="xla.REF.simons.2004.367">Simons et al 2004</xref>].</p>
          <p>Approximately 10% of males with a hemizygous <italic toggle="yes">BTK</italic> pathogenic variant are not recognized as having immunodeficiency until after age ten years and some not until adulthood [<xref ref-type="bibr" rid="xla.REF.howard.2006.201">Howard et al 2006</xref>, <xref ref-type="bibr" rid="xla.REF.conley.2008.39">Conley et al 2008</xref>]. Some affected males have higher serum immunoglobulin concentrations than expected, but all have very low numbers of B cells.</p>
          <p>The prognosis for individuals with XLA has improved markedly in the last 35 years [<xref ref-type="bibr" rid="xla.REF.howard.2006.201">Howard et al 2006</xref>] as a result of earlier diagnosis, more liberal use of antibiotics, and the development of preparations of gammaglobulin that allow gammaglobulin substitution therapy to achieve normal concentrations of serum IgG. Most individuals lead a normal life. However, approximately 10% develop significant infections despite appropriate therapy and many have chronic pulmonary changes [<xref ref-type="bibr" rid="xla.REF.quartier.1999.589">Quartier et al 1999</xref>].</p>
          <p><bold>Heterozygous females.</bold> A single female with XLA has been reported. Her father had XLA and analysis demonstrated exclusive use of the paternally derived X chromosome as the active X [<xref ref-type="bibr" rid="xla.REF.takada.2004.185">Takada et al 2004</xref>].</p>
        </sec>
        <sec id="xla.GenotypePhenotype_Correlations">
          <title>Genotype-Phenotype Correlations</title>
          <p>No strong correlation is observed between the specific <italic toggle="yes">BTK</italic> pathogenic variant and the severity of disease; however, individuals who have amino acid substitutions or splice defects that occur at sites that are conserved, but not invariant, tend to be older at the time of diagnosis, and have higher serum concentrations of IgM and slightly more B cells in the peripheral circulation [<xref ref-type="bibr" rid="xla.REF.l_pezgranados.2005.690">L&#x000f3;pez-Granados et al 2005</xref>, <xref ref-type="bibr" rid="xla.REF.broides.2006.195">Broides et al 2006</xref>].</p>
        </sec>
        <sec id="xla.Nomenclature">
          <title>Nomenclature</title>
          <p>Bruton called the disorder that he first described in 1952 &#x0201c;agammaglobulinemia.&#x0201d; The X-linked pattern of inheritance was noted shortly after that time.</p>
          <p>In the 50s, 60s, and 70s, the disorder was sometimes called congenital agammaglobulinemia, familial hypogammaglobulinemia or infantile agammaglobulinemia, or simply agammaglobulinemia.</p>
        </sec>
        <sec id="xla.Prevalence">
          <title>Prevalence</title>
          <p>Prevalence of X-linked agammaglobulinemia is approximately 3:1,000,000-6:1,000,000 males in all racial and ethnic groups.</p>
        </sec>
      </sec>
      <sec id="xla.Genetically_Related_Disorders">
        <title>Genetically Related Disorders</title>
        <p>No phenotypes other than those discussed in this <italic toggle="yes">GeneReview</italic> are known to be associated with pathogenic variants in <italic toggle="yes">BTK.</italic></p>
        <p>Approximately 3%-5% of individuals with a <italic toggle="yes">BTK</italic> pathogenic variant have a large deletion that extends through the closely linked gene <italic toggle="yes">TIMM8A</italic> (also called <italic toggle="yes">DDP</italic>) and sometimes through <italic toggle="yes">TAF7L</italic> and <italic toggle="yes">DRP2</italic> [<xref ref-type="bibr" rid="xla.REF.richter.2001.107">Richter et al 2001</xref>, <xref ref-type="bibr" rid="xla.REF.sediv_.2007.640">Sediv&#x000e1; et al 2007</xref>]. Individuals with these multi-gene deletions have XLA and <related-object link-type="booklink" source-id="gene" document-id="ddon" document-type="chapter">deafness-dystonia-optic neuropathy syndrome</related-object> (DDS; also called Mohr-Tranebj&#x000e6;rg syndrome).</p>
      </sec>
      <sec id="xla.Differential_Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Approximately 90% of males who are presumed to have X-linked agammaglobulinemia (XLA) based on early onset of infections, severe hypogammaglobulinemia, and markedly reduced numbers of B cells have detectable pathogenic variants in <italic toggle="yes">BTK</italic> [<xref ref-type="bibr" rid="xla.REF.conley.1998.1034">Conley et al 1998</xref>].</p>
        <p>The majority of females with an XLA-like phenotype and males with an XLA phenotype who do not have an identifiable <italic toggle="yes">BTK</italic> pathogenic variant are likely to have defects in other genes required for normal B-cell development (see <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/phenotypicSeries/PS601495">Agammaglobulinemia: OMIM Phenotypic Series</ext-link> to view genes associated with agammaglobulinemia in OMIM). These autosomal recessive forms of agammaglobulinemia are very rare.</p>
        <list list-type="bullet">
          <list-item>
            <p>At least thirty individuals with more than 20 different pathogenic variants in <italic toggle="yes">IGHM</italic> (encoding Ig &#x003bc; chain C region) have been reported [<xref ref-type="bibr" rid="xla.REF.lopez_granados.2002.1029">Lopez Granados et al 2002</xref>, <xref ref-type="bibr" rid="xla.REF.ferrari.2007b.325">Ferrari et al 2007b</xref>, <xref ref-type="bibr" rid="xla.REF.van_zelm.2008.320">van Zelm et al 2008</xref>]. These individuals tend to come to medical attention at an earlier age and are more likely to have life-threatening infections than individuals with XLA, but clinical overlap is considerable.</p>
          </list-item>
          <list-item>
            <p>Defects in Ig&#x003b1; (<italic toggle="yes">CD79A</italic>), Ig&#x003b2; (<italic toggle="yes">CD79B</italic>), &#x003bb;5 (<italic toggle="yes">IGLL1</italic>), <italic toggle="yes">BLNK</italic>, or <italic toggle="yes">PIK3R1</italic> have been reported in fewer than five individuals each. Individuals with any of these five genetic defects cannot be distinguished by routine clinical or laboratory tests from individuals with XLA [<xref ref-type="bibr" rid="xla.REF.conley.2005.216">Conley et al 2005</xref>, <xref ref-type="bibr" rid="xla.REF.dobbs.2007.2055">Dobbs et al 2007</xref>, <xref ref-type="bibr" rid="xla.REF.ferrari.2007a.2047">Ferrari et al 2007a</xref>, <xref ref-type="bibr" rid="xla.REF.conley.2012.463">Conley et al 2012</xref>, <xref ref-type="bibr" rid="xla.REF.bergl_f.2013.1205">Bergl&#x000f6;f et al 2013</xref>].</p>
          </list-item>
        </list>
        <p>These disorders should be considered in females who have an XLA-like phenotype or in males who were presumed to have XLA but who do not have a pathogenic variant in <italic toggle="yes">BTK.</italic> Families with a known history of consanguinity are more likely to have rare autosomal recessive forms of agammaglobulinemia than XLA.</p>
        <p>The underlying defect remains unknown in approximately 5% of individuals with congenital agammaglobulinemia and absent B cells.</p>
        <p>Low concentrations of serum immunoglobulins can be seen in a variety of conditions, including the following X-linked disorders:</p>
        <list list-type="bullet">
          <list-item>
            <p><related-object link-type="booklink" source-id="gene" document-id="xlhi" document-type="chapter">X-linked hyper IgM syndrome</related-object> (also known as CD40 ligand deficiency)</p>
          </list-item>
          <list-item>
            <p>
              <related-object link-type="booklink" source-id="gene" document-id="x-scid" document-type="chapter">X-linked severe combined immunodeficiency</related-object>
            </p>
          </list-item>
          <list-item>
            <p>
              <related-object link-type="booklink" source-id="gene" document-id="x-lpd" document-type="chapter">X-linked lymphoproliferative disease</related-object>
            </p>
          </list-item>
        </list>
        <p>However, individuals with these disorders usually have relatively normal or elevated numbers of B cells.</p>
      </sec>
      <sec id="xla.Management">
        <title>Management</title>
        <sec id="xla.Evaluations_Following_Initial_Diagno">
          <title>Evaluations Following Initial Diagnosis</title>
          <p>To establish the extent of disease and needs of an individual diagnosed with X-linked agammaglobulinemia (XLA), the following evaluations are recommended:</p>
          <list list-type="bullet">
            <list-item>
              <p>A complete blood count with differential</p>
            </list-item>
            <list-item>
              <p>Chemistries that include renal and liver function tests, total protein, albumin, and CRP</p>
            </list-item>
            <list-item>
              <p>Quantitative serum immunoglobulins and titers to vaccine antigens as baseline measurements prior to initiation of gammaglobulin substitution therapy</p>
            </list-item>
            <list-item>
              <p>Baseline chest and sinus x-rays</p>
            </list-item>
            <list-item>
              <p>If the patient is able to cooperate, base line pulmonary function tests</p>
            </list-item>
            <list-item>
              <p>Consultation with a clinical geneticist and/or genetic counselor</p>
            </list-item>
          </list>
        </sec>
        <sec id="xla.Treatment_of_Manifestations">
          <title>Treatment of Manifestations</title>
          <p>Individuals with XLA should receive specialty care at a center with expertise in this disorder.</p>
          <p>If individuals develop acute infections, they should be treated with a course of antibiotics that is at least twice as long as that used in otherwise healthy individuals. Generous use of antibiotics is recommended and treatment should be given without any unnecessary delay.</p>
        </sec>
        <sec id="xla.Prevention_of_Primary_Manifestations">
          <title>Prevention of Primary Manifestations</title>
          <sec id="xla.Bacterial_Infections">
            <title>Bacterial Infections</title>
            <p><bold>Gammaglobulin substitution</bold> therapy is the mainstay of treatment for individuals with XLA. Most individuals in the United States are given approximately 400 mg/kg of gammaglobulin every four weeks. In the past, the majority of individuals received their gammaglobulin by intravenous infusion every two to four weeks. In the last few years, an increasing proportion of individuals have been receiving gammaglobulin by weekly subcutaneous injections. Both routes provide good therapeutic concentrations of serum IgG. The choice of route may depend on factors related to the convenience of the physician and patient [<xref ref-type="bibr" rid="xla.REF.berger.2004.1">Berger 2004</xref>].</p>
            <p>A variety of brands of gammaglobulin are available; none has proven to be superior to others as measured by efficacy or side effects. Occasionally, individuals with XLA have a reaction to gammaglobulin, consisting of headaches, chills, backache, or nausea. These reactions are more likely to occur when the individual has an intercurrent viral infection or when the brand of gammaglobulin has been changed. Such reactions may disappear over time.</p>
            <p><bold>Chronic prophylactic antibiotics</bold> are used in some centers for prevention of bacterial infections.</p>
          </sec>
        </sec>
        <sec id="xla.Prevention_of_Secondary_Complication">
          <title>Prevention of Secondary Complications</title>
          <p>Children with XLA should only be given inactivated polio vaccine (IPV) and not oral polio vaccine.</p>
          <p>The sibs of children with XLA should also be given IPV rather than oral polio vaccine (in order to avoid infecting their affected sib with live virus).</p>
        </sec>
        <sec id="xla.Surveillance">
          <title>Surveillance</title>
          <p>At least once a year:</p>
          <list list-type="bullet">
            <list-item>
              <p>A complete blood count with differential, chemistries, and quantitative serum immunoglobulins to monitor gammaglobulin substitution therapy</p>
            </list-item>
            <list-item>
              <p>Chest x-rays or CTs and sinus films</p>
              <p>Note: Chronic lung disease can develop in the absence of an acute pulmonary infection [<xref ref-type="bibr" rid="xla.REF.quartier.1999.589">Quartier et al 1999</xref>].</p>
            </list-item>
          </list>
          <p>If the patient is stable, the serum IgG does not need to be evaluated with every infusion of gammaglobulin.</p>
        </sec>
        <sec id="xla.AgentsCircumstances_to_Avoid">
          <title>Agents/Circumstances to Avoid</title>
          <p>Live viral vaccines, particularly oral polio vaccine, should be avoided in individuals with XLA.</p>
        </sec>
        <sec id="xla.Evaluation_of_Relatives_at_Risk">
          <title>Evaluation of Relatives at Risk</title>
          <p>It is appropriate to evaluate at-risk male relatives as soon after birth as possible so that gammaglobulin substitution therapy can be initiated promptly and administration of live viral vaccines can be avoided. Evaluations can include:</p>
          <list list-type="bullet">
            <list-item>
              <p>Molecular genetic testing for the known family-specific <italic toggle="yes">BTK</italic> pathogenic variant;</p>
            </list-item>
            <list-item>
              <p>Analysis of the percentage of B cells in the peripheral circulation.</p>
            </list-item>
          </list>
          <p>Note: Serum immunoglobulins will not be helpful in the evaluation of a newborn or infant because maternal IgG crosses the placenta.</p>
          <p>See <xref ref-type="sec" rid="xla.Related_Genetic_Counseling_Issues">Genetic Counseling</xref> for issues related to testing of at-risk relatives for genetic counseling purposes.</p>
        </sec>
        <sec id="xla.Therapies_Under_Investigation">
          <title>Therapies Under Investigation</title>
          <p>Research studies exploring gene therapy for XLA have been conducted in mice [<xref ref-type="bibr" rid="xla.REF.kerns.2010.2146">Kerns et al 2010</xref>, <xref ref-type="bibr" rid="xla.REF.ng.2010.1617">Ng et al 2010</xref>, <xref ref-type="bibr" rid="xla.REF.bestas.2014.4067">Bestas et al 2014</xref>], but it is not clear when this type of treatment may be available for humans.</p>
          <p>Search <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://clinicaltrials.gov/">ClinicalTrials.gov</ext-link> for access to information on clinical studies for a wide range of diseases and conditions.</p>
        </sec>
      </sec>
      <sec id="xla.Genetic_Counseling">
        <title>Genetic Counseling</title>
        <sec id="xla.Mode_of_Inheritance">
          <title>Mode of Inheritance</title>
          <p>X-linked agammaglobulinemia is inherited in an X-linked manner.</p>
        </sec>
        <sec id="xla.Risk_to_Family_Members">
          <title>Risk to Family Members</title>
          <p>
            <bold>Parents of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The father of an affected male will not have the disorder nor will he be hemizygous for the <italic toggle="yes">BTK</italic> pathogenic variant; therefore, he does not require further evaluation/testing.</p>
            </list-item>
            <list-item>
              <p>In a family with more than one affected individual, the mother of an affected male is an obligate heterozygote (carrier).</p>
            </list-item>
            <list-item>
              <p>If a woman has more than one affected child and no other affected relatives and if the <italic toggle="yes">BTK</italic> pathogenic variant cannot be detected in her leukocyte DNA, she has germline mosaicism. Germline mosaicism has been observed [<xref ref-type="bibr" rid="xla.REF.sakamoto.2001.234">Sakamoto et al 2001</xref>].</p>
            </list-item>
            <list-item>
              <p>If an affected male is the only affected family member (50% of affected males represent simplex cases), there are two possibilities:</p>
              <list list-type="bullet">
                <list-item>
                  <p>The mother is a carrier (~80%-85% of cases).</p>
                </list-item>
                <list-item>
                  <p>The affected male has a <italic toggle="yes">de novo</italic> pathogenic variant, in which case the mother is not a carrier (~15%-20% of cases)</p>
                </list-item>
              </list>
            </list-item>
          </list>
          <p>
            <bold>Sibs of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The risk to sibs depends on the genetic status of the mother.</p>
            </list-item>
            <list-item>
              <p>If the mother is a carrier, the chance of transmitting the pathogenic variant in each pregnancy is 50%. Males who inherit the pathogenic variant will be affected; females who inherit the pathogenic variant will be carriers and are highly unlikely to be affected.</p>
            </list-item>
            <list-item>
              <p>Germline mosaicism has been observed [<xref ref-type="bibr" rid="xla.REF.sakamoto.2001.234">Sakamoto et al 2001</xref>]. Thus, if an affected male represents a single case in a family and if the <italic toggle="yes">BTK</italic> pathogenic variant cannot be detected in the leukocyte DNA of his mother, the male sibs are still at increased risk (&#x0003c;5%) of being affected.</p>
            </list-item>
          </list>
          <p><bold>Offspring of a proband.</bold> Affected males transmit the <italic toggle="yes">BTK</italic> pathogenic variant to:</p>
          <list list-type="bullet">
            <list-item>
              <p>All of their daughters, who will be carriers and are not likely to be affected;</p>
            </list-item>
            <list-item>
              <p>None of their sons.</p>
            </list-item>
          </list>
          <p>
            <bold>Other family members</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>A male proband's maternal aunts may be at risk of being heterozygotes (carriers) for the pathogenic variant and the aunts&#x02019; offspring, depending on their gender, may be at risk of being heterozygotes (carriers) for the pathogenic variant or of being affected.</p>
            </list-item>
            <list-item>
              <p>Linkage analysis has shown that the maternal grandfather is the source of a <italic toggle="yes">de novo</italic> pathogenic variant in the majority of males who have no family history of XLA and that the maternal grandmothers are carriers less than 20% of the time [<xref ref-type="bibr" rid="xla.REF.conley.1998.1034">Conley et al 1998</xref>]. Therefore, the risk that the maternal aunt of a boy with no family history of XLA is a carrier is less than 10%.</p>
            </list-item>
          </list>
        </sec>
        <sec id="xla.Heterozygote_Carrier_Detection">
          <title>Heterozygote (Carrier) Detection</title>
          <p>Molecular genetic testing of at-risk female relatives to determine their genetic status is most informative if the <italic toggle="yes">BTK</italic> pathogenic variant has been identified in the proband.</p>
          <p>Note: (1) Females who are heterozygous (carriers) for this X-linked disorder are not likely to be affected. (2) Identification of female heterozygotes requires either (a) prior identification of the <italic toggle="yes">BTK</italic> pathogenic variant in the family or, (b) if an affected male is not available for testing, molecular genetic testing first by sequence analysis, and if no pathogenic variant is identified, by gene-targeted deletion/duplication analysis.</p>
        </sec>
        <sec id="xla.Related_Genetic_Counseling_Issues">
          <title>Related Genetic Counseling Issues</title>
          <p>See Management, <xref ref-type="sec" rid="xla.Evaluation_of_Relatives_at_Risk">Evaluation of Relatives at Risk</xref> for information on evaluating at-risk relatives for the purpose of early diagnosis and treatment.</p>
          <p>
            <bold>Family planning</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The optimal time for determination of genetic risk, clarification of carrier status, and discussion of the availability of prenatal testing is before pregnancy.</p>
            </list-item>
            <list-item>
              <p>It is appropriate to offer genetic counseling (including discussion of potential risks to offspring and reproductive options) to young adults who are affected, are carriers, or are at risk of being carriers.</p>
            </list-item>
          </list>
          <p><bold>DNA banking</bold> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of affected individuals.</p>
        </sec>
        <sec id="xla.Prenatal_Testing_and_Preimplantation">
          <title>Prenatal Testing and Preimplantation Genetic Diagnosis</title>
          <p>Once the <italic toggle="yes">BTK</italic> pathogenic variant has been identified in an affected family member, prenatal testing for a pregnancy at increased risk and preimplantation genetic diagnosis for X-linked agammaglobulinemia are possible.</p>
          <p>Differences in perspective may exist among medical professionals and within families regarding the use of prenatal testing, particularly if the testing is being considered for the purpose of pregnancy termination rather than early diagnosis. Although most centers would consider decisions about prenatal testing to be the choice of the parents, discussion of these issues is appropriate.</p>
        </sec>
      </sec>
      <sec id="xla.Resources">
        <title>Resources</title>
      </sec>
      <sec id="xla.Molecular_Genetics">
        <title>Molecular Genetics</title>
        <p><bold>Gene structure.</bold>
<italic toggle="yes">BTK</italic> has 19 exons spread over 37 kb based on reference sequence <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/nuccore/NM_000061.2">NM_000061.2</ext-link> [<xref ref-type="bibr" rid="xla.REF.sideras.1994.5607">Sideras et al 1994</xref>]. See <related-object source-id="gene" document-id="xla" object-id="xla.molgen.TA">Table A</related-object>, <bold>Gene</bold> for a detailed summary of gene and protein information.</p>
        <p><bold>Pathogenic variants.</bold> More than 600 different pathogenic variants in <italic toggle="yes">BTK</italic> have been reported, and no single pathogenic variant accounts for more than 3% of individuals [<xref ref-type="bibr" rid="xla.REF.holinskifeder.1998.276">Holinski-Feder et al 1998</xref>, <xref ref-type="bibr" rid="xla.REF.vihinen.1999.280">Vihinen et al 1999</xref>, <xref ref-type="bibr" rid="xla.REF.conley.2005.216">Conley et al 2005</xref>, <xref ref-type="bibr" rid="xla.REF.lindvall.2005.200">Lindvall et al 2005</xref>, <xref ref-type="bibr" rid="xla.REF.v_liaho.2006.1209">V&#x000e4;liaho et al 2006</xref>, <xref ref-type="bibr" rid="xla.REF.v_liaho.2015.638">V&#x000e4;liaho et al 2015</xref>].</p>
        <p>Two thirds of pathogenic variants are premature stop codons, splice defects, or frameshift variants. These variants result in improper processing of the <italic toggle="yes">BTK</italic> message. Therefore, no <italic toggle="yes">BTK</italic> message can be identified in the cytoplasm.</p>
        <p>Approximately one third of pathogenic variants are amino acid substitutions; however, approximately two thirds of these pathogenic variants appear to make the protein unstable (for more information, see <related-object source-id="gene" document-id="xla" object-id="xla.molgen.TA">Table A</related-object>).</p>
        <p>Several deep intronic pathogenic variants that would not be detected by routine sequence analysis have been reported [<xref ref-type="bibr" rid="xla.REF.kralovicova.2011.7077">Kralovicova et al 2011</xref>, <xref ref-type="bibr" rid="xla.REF.mohiuddin.2013.1717">Mohiuddin et al 2013</xref>, <xref ref-type="bibr" rid="xla.REF.rattanachartnarong.2014.431">Rattanachartnarong et al 2014</xref>].</p>
        <p>Approximately 3%-5% of affected individuals who have a large deletion that extends through neighboring genes have XLA and <related-object link-type="booklink" source-id="gene" document-id="ddon" document-type="chapter">deafness-dystonia-optic neuropathy syndrome</related-object> (DDS, also called Mohr-Tranebj&#x000e6;rg syndrome; see <xref ref-type="sec" rid="xla.Genetically_Related_Disorders">Genetically Related Disorders</xref>).</p>
        <p><bold>Normal gene product.</bold> The normal <italic toggle="yes">BTK</italic> product has 659 amino acid residues and is expressed in hematopoietic progenitors, myeloid cells and platelets, and B lineage cells [RefSeq <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=NP_000052.1">NP_000052.1</ext-link>].</p>
        <p><bold>Abnormal gene product.</bold> The protein is absent in more than 85% of individuals with XLA.</p>
      </sec>
      <sec id="xla.References">
        <title>References</title>
        <sec id="xla.Literature_Cited">
          <title>Literature Cited</title>
          <ref-list id="xla.Literature_Cited.reflist0">
            <ref id="xla.REF.bearden.2016">
              <mixed-citation publication-type="other">Bearden D, Collett M, Quan PL, Costa-Carvalho BT, Sullivan KE (2016) Enteroviruses in X-linked agammaglobulinemia: update on epidemiology and therapy. J Allergy Clin Immunol Pract. Epub ahead of print</mixed-citation>
            </ref>
            <ref id="xla.REF.berger.2004.1">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Berger</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Subcutaneous immunoglobulin replacement in primary immunodeficiencies.</article-title>
                <source>Clin Immunol</source>
                <volume>112</volume>
                <fpage>1</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">15207776</pub-id>
              </element-citation>
            </ref>
            <ref id="xla.REF.bergl_f.2013.1205">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Bergl&#x000f6;f</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Turunen</surname>
                    <given-names>JJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gissberg</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bestas</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Blomberg</surname>
                    <given-names>KE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Smith</surname>
                    <given-names>CI</given-names>
                  </name>
                </person-group>
                <article-title>Agammaglobulinemia: causative mutations and their implications for novel therapies.</article-title>
                <source>Expert Rev Clin Immunol.</source>
                <year>2013</year>
                <volume>9</volume>
                <fpage>1205</fpage>
                <lpage>21</lpage>
                <pub-id pub-id-type="pmid">24215410</pub-id>
              </element-citation>
            </ref>
            <ref id="xla.REF.bestas.2014.4067">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Bestas</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moreno</surname>
                    <given-names>PM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Blomberg</surname>
                    <given-names>KE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mohammad</surname>
                    <given-names>DK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Saleh</surname>
                    <given-names>AF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sutlu</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nordin</surname>
                    <given-names>JZ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Guterstam</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gustafsson</surname>
                    <given-names>MO</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kharazi</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pi&#x00105;tosa</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Roberts</surname>
                    <given-names>TC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Behlke</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wood</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gait</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lundin</surname>
                    <given-names>KE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>El Andaloussi</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>M&#x000e5;nsson</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bergl&#x000f6;f</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wengel</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Smith</surname>
                    <given-names>CI</given-names>
                  </name>
                </person-group>
                <article-title>Splice-correcting oligonucleotides restore BTK function in X-linked agammaglobulinemia model.</article-title>
                <source>J Clin Invest.</source>
                <year>2014</year>
                <volume>124</volume>
                <fpage>4067</fpage>
                <lpage>81</lpage>
                <pub-id pub-id-type="pmid">25105368</pub-id>
              </element-citation>
            </ref>
            <ref id="xla.REF.broides.2006.195">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Broides</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yang</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Conley</surname>
                    <given-names>ME</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Genotype/phenotype correlations in X-linked agammaglobulinemia.</article-title>
                <source>Clin Immunol</source>
                <volume>118</volume>
                <fpage>195</fpage>
                <lpage>200</lpage>
                <pub-id pub-id-type="pmid">16297664</pub-id>
              </element-citation>
            </ref>
            <ref id="xla.REF.conley.1985.3070">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Conley</surname>
                    <given-names>ME</given-names>
                  </name>
                </person-group>
                <year>1985</year>
                <article-title>B cells in patients with X-linked agammaglobulinemia.</article-title>
                <source>J Immunol</source>
                <volume>134</volume>
                <fpage>3070</fpage>
                <lpage>4</lpage>
                <pub-id pub-id-type="pmid">3920309</pub-id>
              </element-citation>
            </ref>
            <ref id="xla.REF.conley.2005.216">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Conley</surname>
                    <given-names>ME</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Broides</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hernandez-Trujillo</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Howard</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kanegane</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Miyawaki</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shurtleff</surname>
                    <given-names>SA</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Genetic analysis of patients with defects in early B-cell development.</article-title>
                <source>Immunol Rev</source>
                <volume>203</volume>
                <fpage>216</fpage>
                <lpage>34</lpage>
                <pub-id pub-id-type="pmid">15661032</pub-id>
              </element-citation>
            </ref>
            <ref id="xla.REF.conley.2012.463">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Conley</surname>
                    <given-names>ME</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dobbs</surname>
                    <given-names>AK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Quintana</surname>
                    <given-names>AM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bosompem</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wang</surname>
                    <given-names>YD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Coustan-Smith</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Smith</surname>
                    <given-names>AM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Perez</surname>
                    <given-names>EE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Murray</surname>
                    <given-names>PJ</given-names>
                  </name>
                </person-group>
                <article-title>Agammaglobulinemia and absent B lineage cells in a patient lacking the p85&#x003b1; subunit of PI3K.</article-title>
                <source>J Exp Med.</source>
                <year>2012</year>
                <volume>209</volume>
                <fpage>463</fpage>
                <lpage>70</lpage>
                <pub-id pub-id-type="pmid">22351933</pub-id>
              </element-citation>
            </ref>
            <ref id="xla.REF.conley.2008.39">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Conley</surname>
                    <given-names>ME</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Farmer</surname>
                    <given-names>DM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dobbs</surname>
                    <given-names>AK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Howard</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aiba</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shurtleff</surname>
                    <given-names>SA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kurosaki</surname>
                    <given-names>T</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>A minimally hypomorphic mutation in Btk resulting in reduced B cell numbers but no clinical disease.</article-title>
                <source>Clin Exp Immunol</source>
                <volume>152</volume>
                <fpage>39</fpage>
                <lpage>44</lpage>
                <pub-id pub-id-type="pmid">18241230</pub-id>
              </element-citation>
            </ref>
            <ref id="xla.REF.conley.2002.566">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Conley</surname>
                    <given-names>ME</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Howard</surname>
                    <given-names>V</given-names>
                  </name>
                </person-group>
                <year>2002</year>
                <article-title>Clinical findings leading to the diagnosis of X-linked agammaglobulinemia.</article-title>
                <source>J Pediatr</source>
                <volume>141</volume>
                <fpage>566</fpage>
                <lpage>71</lpage>
                <pub-id pub-id-type="pmid">12378199</pub-id>
              </element-citation>
            </ref>
            <ref id="xla.REF.conley.1998.1034">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Conley</surname>
                    <given-names>ME</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mathias</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Treadaway</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Minegishi</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rohrer</surname>
                    <given-names>J</given-names>
                  </name>
                </person-group>
                <year>1998</year>
                <article-title>Mutations in BTK in patients with presumed X-linked agammaglobulinemia.</article-title>
                <source>Am J Hum Genet</source>
                <volume>62</volume>
                <fpage>1034</fpage>
                <lpage>43</lpage>
                <pub-id pub-id-type="pmid">9545398</pub-id>
              </element-citation>
            </ref>
            <ref id="xla.REF.cuccherini.2000.121">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Cuccherini</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chua</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gill</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Weir</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wray</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stewart</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nelson</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fuss</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Strober</surname>
                    <given-names>W</given-names>
                  </name>
                </person-group>
                <year>2000</year>
                <article-title>Bacteremia and skin/bone infections in two patients with X-linked agammaglobulinemia caused by an unusual organism related to Flexispira/Helicobacter species.</article-title>
                <source>Clin Immunol</source>
                <volume>97</volume>
                <fpage>121</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">11027452</pub-id>
              </element-citation>
            </ref>
            <ref id="xla.REF.dobbs.2007.2055">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Dobbs</surname>
                    <given-names>AK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yang</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Farmer</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kager</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Parolini</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Conley</surname>
                    <given-names>ME</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>Cutting edge: a hypomorphic mutation in Igbeta (CD79b) in a patient with immunodeficiency and a leaky defect in B cell development.</article-title>
                <source>J Immunol</source>
                <volume>179</volume>
                <fpage>2055</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">17675462</pub-id>
              </element-citation>
            </ref>
            <ref id="xla.REF.ferrari.2007a.2047">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ferrari</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lougaris</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Caraffi</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zuntini</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yang</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Soresina</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Meini</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cazzola</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rossi</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Reth</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Plebani</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>2007a</year>
                <article-title>Mutations of the Igbeta gene cause agammaglobulinemia in man.</article-title>
                <source>J Exp Med</source>
                <volume>204</volume>
                <fpage>2047</fpage>
                <lpage>51</lpage>
                <pub-id pub-id-type="pmid">17709424</pub-id>
              </element-citation>
            </ref>
            <ref id="xla.REF.ferrari.2007b.325">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ferrari</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zuntini</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lougaris</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Soresina</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sourkov&#x000e1;</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fiorini</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Martino</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rossi</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pietrogrande</surname>
                    <given-names>MC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Martire</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Spadaro</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cardinale</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cossu</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pierani</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Quinti</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rossi</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Plebani</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>2007b</year>
                <article-title>Molecular analysis of the pre-BCR complex in a large cohort of patients affected by autosomal-recessive agammaglobulinemia.</article-title>
                <source>Genes Immun</source>
                <volume>8</volume>
                <fpage>325</fpage>
                <lpage>33</lpage>
                <pub-id pub-id-type="pmid">17410177</pub-id>
              </element-citation>
            </ref>
            <ref id="xla.REF.holinskifeder.1998.276">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Holinski-Feder</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Weiss</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brandau</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jedele</surname>
                    <given-names>KB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nore</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Backesjo</surname>
                    <given-names>CM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vihinen</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hubbard</surname>
                    <given-names>SR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Belohradsky</surname>
                    <given-names>BH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Smith</surname>
                    <given-names>CI</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Meindl</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>1998</year>
                <article-title>Mutation screening of the BTK gene in 56 families with X-linked agammaglobulinemia (XLA): 47 unique mutations without correlation to clinical course.</article-title>
                <source>Pediatrics</source>
                <volume>101</volume>
                <fpage>276</fpage>
                <lpage>84</lpage>
                <pub-id pub-id-type="pmid">9445504</pub-id>
              </element-citation>
            </ref>
            <ref id="xla.REF.howard.2006.201">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Howard</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Greene</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pahwa</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Winkelstein</surname>
                    <given-names>JA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Boyle</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kocak</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Conley</surname>
                    <given-names>ME</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>The health status and quality of life of adults with X-linked agammaglobulinemia.</article-title>
                <source>Clin Immunol</source>
                <volume>118</volume>
                <fpage>201</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">16377251</pub-id>
              </element-citation>
            </ref>
            <ref id="xla.REF.kerns.2010.2146">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kerns</surname>
                    <given-names>HM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ryu</surname>
                    <given-names>BY</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stirling</surname>
                    <given-names>BV</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sather</surname>
                    <given-names>BD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Astrakhan</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Humblet-Baron</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Liggitt</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rawlings</surname>
                    <given-names>DJ</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>B cell-specific lentiviral gene therapy leads to sustained B-cell functional recovery in a murine model of X-linked agammaglobulinemia.</article-title>
                <source>Blood.</source>
                <volume>115</volume>
                <fpage>2146</fpage>
                <lpage>55</lpage>
                <pub-id pub-id-type="pmid">20093406</pub-id>
              </element-citation>
            </ref>
            <ref id="xla.REF.kralovicova.2011.7077">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kralovicova</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hwang</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Asplund</surname>
                    <given-names>AC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Churbanov</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Smith</surname>
                    <given-names>CIE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vorechovsky</surname>
                    <given-names>I</given-names>
                  </name>
                </person-group>
                <article-title>Compensatory signals associated with the activation of human GC 5' splice sites.</article-title>
                <source>Nucleic Acids Res.</source>
                <year>2011</year>
                <volume>39</volume>
                <fpage>7077</fpage>
                <lpage>91</lpage>
                <pub-id pub-id-type="pmid">21609956</pub-id>
              </element-citation>
            </ref>
            <ref id="xla.REF.lederman.1985.145">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Lederman</surname>
                    <given-names>HM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Winkelstein</surname>
                    <given-names>JA</given-names>
                  </name>
                </person-group>
                <year>1985</year>
                <article-title>X-linked agammaglobulinemia: an analysis of 96 patients.</article-title>
                <source>Medicine (Baltimore)</source>
                <volume>64</volume>
                <fpage>145</fpage>
                <lpage>56</lpage>
                <pub-id pub-id-type="pmid">2581110</pub-id>
              </element-citation>
            </ref>
            <ref id="xla.REF.lindvall.2005.200">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Lindvall</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Blomberg</surname>
                    <given-names>KE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Valiaho</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vargas</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Heinonen</surname>
                    <given-names>JE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Berglof</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mohamed</surname>
                    <given-names>AJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nore</surname>
                    <given-names>BF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vihinen</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Smith</surname>
                    <given-names>CI</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Bruton's tyrosine kinase: cell biology, sequence conservation, mutation spectrum, siRNA modifications, and expression profiling.</article-title>
                <source>Immunol Rev</source>
                <volume>203</volume>
                <fpage>200</fpage>
                <lpage>15</lpage>
                <pub-id pub-id-type="pmid">15661031</pub-id>
              </element-citation>
            </ref>
            <ref id="xla.REF.l_pezgranados.2005.690">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>L&#x000f3;pez-Granados</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>P&#x000e9;rez de Diego</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ferreira Cerd&#x000e1;n</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Font&#x000e1;n Casariego</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Garc&#x000ed;a Rodr&#x000ed;guez</surname>
                    <given-names>MC</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>A genotype-phenotype correlation study in a group of 54 patients with X-linked agammaglobulinemia.</article-title>
                <source>J.Allergy Clin.Immunol</source>
                <volume>116</volume>
                <fpage>690</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">16159644</pub-id>
              </element-citation>
            </ref>
            <ref id="xla.REF.lopez_granados.2002.1029">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Lopez Granados</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Porpiglia</surname>
                    <given-names>AS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hogan</surname>
                    <given-names>MB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Matamoros</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Krasovec</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pignata</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Smith</surname>
                    <given-names>CI</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hammarstrom</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bjorkander</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Belohradsky</surname>
                    <given-names>BH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Casariego</surname>
                    <given-names>GF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Garcia Rodriguez</surname>
                    <given-names>MC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Conley</surname>
                    <given-names>ME</given-names>
                  </name>
                </person-group>
                <year>2002</year>
                <article-title>Clinical and molecular analysis of patients with defects in micro heavy chain gene.</article-title>
                <source>J Clin Invest</source>
                <volume>110</volume>
                <fpage>1029</fpage>
                <lpage>35</lpage>
                <pub-id pub-id-type="pmid">12370281</pub-id>
              </element-citation>
            </ref>
            <ref id="xla.REF.misbah.1992.266">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Misbah</surname>
                    <given-names>SA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Spickett</surname>
                    <given-names>GP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ryba</surname>
                    <given-names>PC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hockaday</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kroll</surname>
                    <given-names>JS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sherwood</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kurtz</surname>
                    <given-names>JB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moxon</surname>
                    <given-names>ER</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chapel</surname>
                    <given-names>HM</given-names>
                  </name>
                </person-group>
                <year>1992</year>
                <article-title>Chronic enteroviral meningoencephalitis in agammaglobulinemia: case report and literature review.</article-title>
                <source>J Clin Immunol</source>
                <volume>12</volume>
                <fpage>266</fpage>
                <lpage>70</lpage>
                <pub-id pub-id-type="pmid">1512300</pub-id>
              </element-citation>
            </ref>
            <ref id="xla.REF.mohiuddin.2013.1717">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Mohiuddin</surname>
                    <given-names>MS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Abbott</surname>
                    <given-names>JK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hubbard</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Torgerson</surname>
                    <given-names>TR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ochs</surname>
                    <given-names>HD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gelfand</surname>
                    <given-names>EW</given-names>
                  </name>
                </person-group>
                <article-title>Diagnosis and evaluation of primary panhypogammaglobulinemia: a molecular and genetic challenge.</article-title>
                <source>J Allergy Clin Immunol.</source>
                <year>2013</year>
                <volume>131</volume>
                <fpage>1717</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">23726535</pub-id>
              </element-citation>
            </ref>
            <ref id="xla.REF.ng.2010.1617">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ng</surname>
                    <given-names>YY</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Baert</surname>
                    <given-names>MR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pike-Overzet</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rodijk</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brugman</surname>
                    <given-names>MH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schambach</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Baum</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hendriks</surname>
                    <given-names>RW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van Dongen</surname>
                    <given-names>JJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Staal</surname>
                    <given-names>FJ</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>Correction of B-cell development in Btk-deficient mice using lentiviral vectorswith codon-optimized human BTK.</article-title>
                <source>Leukemia.</source>
                <volume>24</volume>
                <fpage>1617</fpage>
                <lpage>30</lpage>
                <pub-id pub-id-type="pmid">20574453</pub-id>
              </element-citation>
            </ref>
            <ref id="xla.REF.nonoyama.1998.3925">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Nonoyama</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tsukada</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yamadori</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Miyawaki</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jin</surname>
                    <given-names>YZ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Watanabe</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Morio</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yata</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ochs</surname>
                    <given-names>HD</given-names>
                  </name>
                </person-group>
                <year>1998</year>
                <article-title>Functional analysis of peripheral blood B cells in patients with X-linked agammaglobulinemia.</article-title>
                <source>J Immunol</source>
                <volume>161</volume>
                <fpage>3925</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">9780159</pub-id>
              </element-citation>
            </ref>
            <ref id="xla.REF.ochs.1996.287">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ochs</surname>
                    <given-names>HD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Smith</surname>
                    <given-names>CI</given-names>
                  </name>
                </person-group>
                <article-title>X-linked agammaglobulinemia. A clinical and molecular analysis.</article-title>
                <source>Medicine (Baltimore)</source>
                <year>1996</year>
                <volume>75</volume>
                <fpage>287</fpage>
                <lpage>99</lpage>
                <pub-id pub-id-type="pmid">8982147</pub-id>
              </element-citation>
            </ref>
            <ref id="xla.REF.plebani.2002.221">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Plebani</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Soresina</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rondelli</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Amato</surname>
                    <given-names>GM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Azzari</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cardinale</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cazzola</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Consolini</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>De Mattia</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dell'Erba</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Duse</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fiorini</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Martino</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Martire</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Masi</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Monafo</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moschese</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Notarangelo</surname>
                    <given-names>LD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Orlandi</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Panei</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pession</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pietrogrande</surname>
                    <given-names>MC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pignata</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Quinti</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ragno</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rossi</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sciotto</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stabile</surname>
                    <given-names>A</given-names>
                  </name>
                  <collab>Italian Pediatric Group for XLA-AIEOP</collab>
                </person-group>
                <year>2002</year>
                <article-title>Clinical, immunological, and molecular analysis in a large cohort of patiens with X-linked agammaglobulinemia: an Italian multicenter study.</article-title>
                <source>Clin Immunol</source>
                <volume>104</volume>
                <fpage>221</fpage>
                <lpage>30</lpage>
                <pub-id pub-id-type="pmid">12217331</pub-id>
              </element-citation>
            </ref>
            <ref id="xla.REF.quartier.1999.589">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Quartier</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Debre</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>De Blic</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Sauverzac</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sayegh</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jabado</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Haddad</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Blanche</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Casanova</surname>
                    <given-names>JL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Smith</surname>
                    <given-names>CI</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Le Deist</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Saint Basile</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fischer</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>1999</year>
                <article-title>Early and prolonged intravenous immunoglobulin replacement therapy in childhood agammaglobulinemia: a retrospective survey of 31 patients.</article-title>
                <source>J Pediatr</source>
                <volume>134</volume>
                <fpage>589</fpage>
                <lpage>96</lpage>
                <pub-id pub-id-type="pmid">10228295</pub-id>
              </element-citation>
            </ref>
            <ref id="xla.REF.rattanachartnarong.2014.431">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Rattanachartnarong</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tongkobpetch</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chatchatee</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Daengsuwan</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ittiwut</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Suphapeetiporn</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shotelersuk</surname>
                    <given-names>V</given-names>
                  </name>
                </person-group>
                <article-title>In vitro correction of a novel splicing alteration in the BTK gene by using antisense morpholino oligonucleotides.</article-title>
                <source>Arch Immunol Ther Exp (Warsz)</source>
                <year>2014</year>
                <volume>62</volume>
                <fpage>431</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">24658450</pub-id>
              </element-citation>
            </ref>
            <ref id="xla.REF.richter.2001.107">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Richter</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Conley</surname>
                    <given-names>ME</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rohrer</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Myers</surname>
                    <given-names>LA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zahradka</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kelecic</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sertic</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stavljenic-Rukavina</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>2001</year>
                <article-title>A contiguous deletion syndrome of X-linked agammaglobulinemia and sensorineural deafness.</article-title>
                <source>Pediatr Allergy Immunol</source>
                <volume>12</volume>
                <fpage>107</fpage>
                <lpage>11</lpage>
                <pub-id pub-id-type="pmid">11338284</pub-id>
              </element-citation>
            </ref>
            <ref id="xla.REF.sakamoto.2001.234">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Sakamoto</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kanegane</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fujii</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tsukada</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Miyawaki</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shinomiya</surname>
                    <given-names>N</given-names>
                  </name>
                </person-group>
                <article-title>Maternal germinal mosaicism of X-linked agammaglobulinemia.</article-title>
                <source>Am J Med Genet</source>
                <year>2001</year>
                <volume>99</volume>
                <fpage>234</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">11241495</pub-id>
              </element-citation>
            </ref>
            <ref id="xla.REF.sediv_.2007.640">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Sediv&#x000e1;</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Smith</surname>
                    <given-names>CI</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Asplund</surname>
                    <given-names>AC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hadac</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Janda</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zeman</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hans&#x000ed;kov&#x000e1;</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dvor&#x000e1;kov&#x000e1;</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mr&#x000e1;zov&#x000e1;</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Velbri</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Koehler</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Roesch</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sullivan</surname>
                    <given-names>KE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Futatani</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ochs</surname>
                    <given-names>HD</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>Contiguous X-chromosome deletion syndrome encompassing the BTK, TIMM8A, TAF7L, and DRP2 genes.</article-title>
                <source>J Clin Immunol</source>
                <volume>27</volume>
                <fpage>640</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">17851739</pub-id>
              </element-citation>
            </ref>
            <ref id="xla.REF.sideras.1994.5607">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Sideras</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>M&#x000fc;ller</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shiels</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jin</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Khan</surname>
                    <given-names>WN</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nilsson</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Parkinson</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Thomas</surname>
                    <given-names>JD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brand&#x000e9;n</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Larsson</surname>
                    <given-names>I</given-names>
                  </name>
                </person-group>
                <article-title>Genomic organization of mouse and human Bruton's agammaglobulinemia tyrosine kinase (Btk) loci.</article-title>
                <source>J Immunol</source>
                <year>1994</year>
                <volume>153</volume>
                <fpage>5607</fpage>
                <lpage>17</lpage>
                <pub-id pub-id-type="pmid">7989760</pub-id>
              </element-citation>
            </ref>
            <ref id="xla.REF.simons.2004.367">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Simons</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Spacek</surname>
                    <given-names>LA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lederman</surname>
                    <given-names>HM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Winkelstein</surname>
                    <given-names>JA</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Helicobacter cinaedi bacteremia presenting as macules in an afebrile patient with X-linked agammaglobulinemia.</article-title>
                <source>Infection</source>
                <volume>32</volume>
                <fpage>367</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">15597229</pub-id>
              </element-citation>
            </ref>
            <ref id="xla.REF.takada.2004.185">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Takada</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kanegane</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nomura</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yamamoto</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ihara</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Takahashi</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tsukada</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Miyawaki</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hara</surname>
                    <given-names>T</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Female agammaglobulinemia due to the Bruton tyrosine kinase deficiency caused by extremely skewed X-chromosome inactivation.</article-title>
                <source>Blood</source>
                <volume>103</volume>
                <fpage>185</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">12958074</pub-id>
              </element-citation>
            </ref>
            <ref id="xla.REF.v_liaho.2015.638">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>V&#x000e4;liaho</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Faisal</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ortutay</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Smith</surname>
                    <given-names>CI</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vihinen</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <article-title>Characterization of all possible single-nucleotide change caused amino acid substitutions in the kinase domain of Bruton tyrosine kinase.</article-title>
                <source>Hum Mutat</source>
                <year>2015</year>
                <volume>36</volume>
                <fpage>638</fpage>
                <lpage>47</lpage>
                <pub-id pub-id-type="pmid">25777788</pub-id>
              </element-citation>
            </ref>
            <ref id="xla.REF.v_liaho.2006.1209">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>V&#x000e4;liaho</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Smith</surname>
                    <given-names>CI</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vihinen</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>BTKbase: the mutation database for X-linked agammaglobulinemia.</article-title>
                <source>Hum Mutat</source>
                <volume>27</volume>
                <fpage>1209</fpage>
                <lpage>17</lpage>
                <pub-id pub-id-type="pmid">16969761</pub-id>
              </element-citation>
            </ref>
            <ref id="xla.REF.van_zelm.2008.320">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>van Zelm</surname>
                    <given-names>MC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Geertsema</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nieuwenhuis</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Ridder</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Conley</surname>
                    <given-names>ME</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schiff</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tezcan</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bernatowska</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hartwig</surname>
                    <given-names>NG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sanders</surname>
                    <given-names>EA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Litzman</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kondratenko</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van Dongen</surname>
                    <given-names>JJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van der Burg</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>Gross deletions involving IGHM, BTK, or Artemis: a model for genomic lesions mediated by transposable elements.</article-title>
                <source>Am J Hum Genet</source>
                <volume>82</volume>
                <fpage>320</fpage>
                <lpage>32</lpage>
                <pub-id pub-id-type="pmid">18252213</pub-id>
              </element-citation>
            </ref>
            <ref id="xla.REF.vihinen.1999.280">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Vihinen</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kwan</surname>
                    <given-names>SP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lester</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ochs</surname>
                    <given-names>HD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Resnick</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>V&#x000e4;liaho</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Conley</surname>
                    <given-names>ME</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Smith</surname>
                    <given-names>CI</given-names>
                  </name>
                </person-group>
                <year>1999</year>
                <article-title>Mutations of the human BTK gene coding for bruton tyrosine kinase in X-linked agammaglobulinemia.</article-title>
                <source>Hum Mutat.</source>
                <volume>13</volume>
                <fpage>280</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">10220140</pub-id>
              </element-citation>
            </ref>
            <ref id="xla.REF.wilfert.1977.1485">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Wilfert</surname>
                    <given-names>CM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Buckley</surname>
                    <given-names>RH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mohanakumar</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Griffith</surname>
                    <given-names>JF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Katz</surname>
                    <given-names>SL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Whisnant</surname>
                    <given-names>JK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eggleston</surname>
                    <given-names>PA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moore</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Treadwell</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Oxman</surname>
                    <given-names>MN</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rosen</surname>
                    <given-names>FS</given-names>
                  </name>
                </person-group>
                <year>1977</year>
                <article-title>Persistent and fatal central-nervous-system ECHOvirus infections in patients with agammaglobulinemia.</article-title>
                <source>N Engl J Med</source>
                <volume>296</volume>
                <fpage>1485</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">301244</pub-id>
              </element-citation>
            </ref>
            <ref id="xla.REF.winkelstein.2006.193">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Winkelstein</surname>
                    <given-names>JA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Marino</surname>
                    <given-names>MC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lederman</surname>
                    <given-names>HM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jones</surname>
                    <given-names>SM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sullivan</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Burks</surname>
                    <given-names>AW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Conley</surname>
                    <given-names>ME</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cunningham-Rundles</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ochs</surname>
                    <given-names>HD</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>X-linked agammaglobulinemia: report on a United States registry of 201 patients.</article-title>
                <source>Medicine (Baltimore)</source>
                <year>2006</year>
                <volume>85</volume>
                <fpage>193</fpage>
                <lpage>202</lpage>
                <pub-id pub-id-type="pmid">16862044</pub-id>
              </element-citation>
            </ref>
            <ref id="xla.REF.ziegner.2002.19">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ziegner</surname>
                    <given-names>UH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kobayashi</surname>
                    <given-names>RH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cunningham-Rundles</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Espa&#x000f1;ol</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fasth</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Huttenlocher</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Krogstad</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Marthinsen</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Notarangelo</surname>
                    <given-names>LD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pasic</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rieger</surname>
                    <given-names>CH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rudge</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sankar</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shigeoka</surname>
                    <given-names>AO</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stiehm</surname>
                    <given-names>ER</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sullivan</surname>
                    <given-names>KE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Webster</surname>
                    <given-names>AD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ochs</surname>
                    <given-names>HD</given-names>
                  </name>
                </person-group>
                <year>2002</year>
                <article-title>Progressive neurodegeneration in patients with primary immunodeficiency disease on IVIG treatment.</article-title>
                <source>Clin Immunol</source>
                <volume>102</volume>
                <fpage>19</fpage>
                <lpage>24</lpage>
                <pub-id pub-id-type="pmid">11781063</pub-id>
              </element-citation>
            </ref>
          </ref-list>
        </sec>
      </sec>
      <sec id="xla.Chapter_Notes">
        <title>Chapter Notes</title>
        <sec id="xla.Author_History">
          <title>Author History</title>
          <p>Mary Ellen Conley, MD; St Jude Children&#x02019;s Research Hospital (2001-2016)Vanessa C Howard, RN, MSN; St Jude Children&#x02019;s Research Hospital (2001-2016)CI Edvard Smith, MD, PhD (2016-present)Anna Bergl&#x000f6;f, PhD (2016-present)</p>
        </sec>
        <sec id="xla.Revision_History">
          <title>Revision History</title>
          <list list-type="bullet">
            <list-item>
              <p>4 August 2016 (bp) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>17 November 2011 (me) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>30 July 2009 (me) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>21 December 2005 (me) Comprehensive update posted to live Web site</p>
            </list-item>
            <list-item>
              <p>4 November 2004 (mec) Revision: test availability</p>
            </list-item>
            <list-item>
              <p>3 October 2003 (me) Comprehensive update posted to live Web site</p>
            </list-item>
            <list-item>
              <p>5 April 2001 (me) Review posted to live Web site</p>
            </list-item>
            <list-item>
              <p>December 2000 (mec) Original submission</p>
            </list-item>
          </list>
        </sec>
      </sec>
    </body>
  </book-part>
</book-part-wrapper>
